» Articles » PMID: 17200205

Tumor Cell Transendothelial Passage in the Absorbing Lymphatic Vessel of Transgenic Adenocarcinoma Mouse Prostate

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2007 Jan 4
PMID 17200205
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The distribution and fine structure of the tumor-associated absorbing lymphatic vessel in the tumor mass of prostate adenocarcinoma and of seminal vesicle metastasis in transgenic mice was studied for the purpose of understanding the modality of tumor cell transendothelial passage from the extravasal matrix into the lymphatic vessel. In the tumor mass, two main cell populations were identified: stromal tumor cells and the invasive phenotype tumor (IPT) cells, having characteristics such as a highly electron-dense matrix rich in small granules lacking a dense core and massed nuclear chromatin, which is positive to immunostaining with anti-SV40 large T antigen antibody. Based on the ultrastructural pictures of different moments of the IPT cell transendothelial passage by ultrathin serial sections of the tumor-associated absorbing lymphatic vessel, the manner of its transendothelial passage through the intraendothelial channel, without involving intercellular contacts, was demonstrated. The presence of IPT cells in the parenchyma of satellite lymph node highlights its significant role in metastatic diffusion. The intraendothelial channel is the reply to the lack of knowledge regarding the intravasation of the tumor cell into the lymphatic circulation. The lymphatic endothelium would organize this channel on the basis of tumor cell-endothelial cell-extravasal matrix molecular interactions, which are as yet unidentified.

Citing Articles

VE-cadherin junction dynamics in initial lymphatic vessels promotes lymph node metastasis.

Sainz-Jaspeado M, Ring S, Proulx S, Richards M, Martinsson P, Li X Life Sci Alliance. 2023; 7(3).

PMID: 38148112 PMC: 10751244. DOI: 10.26508/lsa.202302168.


Extracellular matrix molecules associated with lymphatic vessels in health and disease.

Czarnowska E, Ratajska A, Jankowska-Steifer E, Flaht-Zabost A, Niderla-Bielinska J Histol Histopathol. 2023; 39(1):13-34.

PMID: 37350542 DOI: 10.14670/HH-18-641.


Buttons and Zippers: Endothelial Junctions in Lymphatic Vessels.

Baluk P, McDonald D Cold Spring Harb Perspect Med. 2022; 12(12).

PMID: 35534209 PMC: 9643678. DOI: 10.1101/cshperspect.a041178.


Endocanalicular transendothelial crossing (ETC): A novel intravasation mode used by HEK-EBNA293-VEGF-D cells during the metastatic process in a xenograft model.

Armando F, Ferrari L, Arcari M, Azzali G, Dallatana D, Ferrari M PLoS One. 2020; 15(10):e0239932.

PMID: 33085676 PMC: 7577447. DOI: 10.1371/journal.pone.0239932.


Traversing the basement membrane in vivo: a diversity of strategies.

Kelley L, Lohmer L, Hagedorn E, Sherwood D J Cell Biol. 2014; 204(3):291-302.

PMID: 24493586 PMC: 3912525. DOI: 10.1083/jcb.201311112.


References
1.
Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H . Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997; 276(5317):1423-5. DOI: 10.1126/science.276.5317.1423. View

2.
Helmlinger G, Netti P, Lichtenbeld H, Melder R, Jain R . Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol. 1997; 15(8):778-83. DOI: 10.1038/nbt0897-778. View

3.
Achen M, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks A . Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998; 95(2):548-53. PMC: 18457. DOI: 10.1073/pnas.95.2.548. View

4.
Perl A, Wilgenbus P, Dahl U, Semb H, Christofori G . A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998; 392(6672):190-3. DOI: 10.1038/32433. View

5.
Azzali G . The lymphatic vessels and the so-called "lymphatic stomata" of the diaphragm: a morphologic ultrastructural and three-dimensional study. Microvasc Res. 1999; 57(1):30-43. DOI: 10.1006/mvre.1998.2101. View